SEC Form 4 · accession 0001179110-19-001452
HALOZYME THERAPEUTICS, INC. · HALO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Helen Torley
Officer — President and CEO · Director
Period of report
Feb 6, 2019
Accepted (ET)
Feb 6, 2019 · 6:02 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001159036
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 6, 2019 | M | 31,250 | $0.00 | A | 396,798 | D | |
| Common StockF1 | Feb 6, 2019 | F | 14,547 | $16.73 | D | 382,251 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF2 | $0.00 | Feb 6, 2019 | M | 31,250 | D | — | — | Common Stock | 31,250 | 0 | D |
Explanation of responses
- F1The reported disposition of 14,547 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations.
- F2This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer.